Free Shipping on orders over $150
1
Awaiting product image

Ipamorelin / CJC-1295 — 5mg / 5mg

Selective GHS-R1a Agonist

Ipamorelin is a synthetic peptide classified as a selective growth hormone secretagogue receptor (GHS-R1a) agonist, carrying an indexed body of research literature spanning human and animal studies, including clinical-context publications.

$45.00

The CJC-1295 (No DAC) / Ipamorelin blend is the gold standard combination protocol for GH secretagogue therapy. CJC-1295 (No DAC) is a GHRH analog that stimulates

Premium Subscribers only. This compound is part of the restricted catalog. Become a Premium subscriber to purchase.
SKU: LL-IPACJC-55 Category:

PubMed Literature Index

52

studies indexed in the public literature

Q2 2026 · view PubMed search ↗

25
Human
45
Animal
2
Clinical Trials
0
EU Trials

Overview

Studies describe Ipamorelin as a highly selective agonist at the Growth Hormone Secretagogue Receptor (GHS-R1a), acting at the pituitary and hypothalamus. In the literature, this receptor selectivity is presented as its defining characteristic, distinguishing it from other growth hormone-releasing peptides such as GHRP-6 and GHRP-2, which are reported to also raise cortisol, prolactin, and ACTH. Research characterizes Ipamorelin's receptor activation as producing a sharp, pulsatile pattern of GH release described as mirroring the body's own endogenous secretion pattern, with the physiological feedback arc reported to remain preserved.

Chemical & Molecular Properties

FormulaC38H49N9O5
Mol. Weight711.9 g/mol
PubChem CID9831659

Key Areas of Research Interest

  • Investigated in the context of growth hormone secretagogue receptor (GHS-R1a) pharmacology and receptor selectivity
  • Investigated in the context of pituitary and hypothalamic signaling pathways involved in GH release
  • Investigated in the context of pulsatile growth hormone secretion patterns
  • Investigated in the context of comparative selectivity against other GH-releasing peptides such as GHRP-6 and GHRP-2
  • Investigated in the context of receptor-mediated effects on cortisol, prolactin, and ACTH release

FAQ

What is Ipamorelin commonly researched for?

Ipamorelin is studied as a selective growth hormone secretagogue receptor (GHS-R1a) agonist, primarily in the context of pituitary and hypothalamic GH-release signaling in laboratory research.

Is Ipamorelin FDA-approved?

No. Sold for laboratory research use only, not FDA-approved, not for human or veterinary consumption.

How is Ipamorelin stored?

Ipamorelin is supplied lyophilized and stored frozen, protected from light; refrigerated after reconstitution for research use.

What purity standard does Legendary Labz hold Ipamorelin to?

Every lot of Ipamorelin is independently third-party tested as part of Legendary Labz' quality standards.

Is a Certificate of Analysis available for Ipamorelin?

Certificates of Analysis for Ipamorelin are published per lot as testing completes.

Materials referenced on this page are intended for laboratory research purposes. No claims regarding therapeutic efficacy are made or implied. Not for human or veterinary use. Not evaluated by the FDA. Must be 21+.

Description

Overview

The CJC-1295 (No DAC) / Ipamorelin blend is the gold standard combination protocol for GH secretagogue therapy. CJC-1295 (No DAC) is a GHRH analog that stimulates the hypothalamus to release GHRH, priming the pituitary for GH secretion. Ipamorelin is a selective GHRP (ghrelin receptor agonist) that triggers pulsatile GH release from the pituitary without the cortisol or prolactin elevation seen with GHRP-2 or GHRP-6. When combined, the GHRH + GHRP synergy amplifies GH pulse magnitude 3-5x greater than either compound alone, mimicking the natural physiological GH release pattern more closely than exogenous HGH. This blend is the preferred starting point for GH optimization in anti-aging, body recomposition, and recovery protocols.

Structure & Chemistry

  • Category: GH SECRETAGOGUE / ANTI-AGING / RECOVERY
  • Molecular size: CJC: ~3.37 kDa | Ipamorelin: ~0.81 kDa (pre-mixed in single vial)

Regulatory & Research Status

  • FDA: Neither component approved for human use. Both removed from Category 2 compounding ban (Sept 2024) for PCAC review, compounding still prohibited pending outcome.
  • WADA: Both compounds Prohibited S2, CJC as GHRH Analog, Ipamorelin as GH Secretagogue. Banned in and out of competition.
  • Evidence: Zero human RCTs on the combination specifically. The 3-5x synergy figure is from pharmacodynamic modeling and animal studies, not confirmed in human clinical trials.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category GH SECRETAGOGUE / ANTI-AGING / RECOVERY
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Reviews

There are no reviews yet.

Be the first to review “Ipamorelin / CJC-1295 — 5mg / 5mg”

Your email address will not be published. Required fields are marked *

Overview

The CJC-1295 (No DAC) / Ipamorelin blend is the gold standard combination protocol for GH secretagogue therapy. CJC-1295 (No DAC) is a GHRH analog that stimulates the hypothalamus to release GHRH, priming the pituitary for GH secretion. Ipamorelin is a selective GHRP (ghrelin receptor agonist) that triggers pulsatile GH release from the pituitary without the cortisol or prolactin elevation seen with GHRP-2 or GHRP-6. When combined, the GHRH + GHRP synergy amplifies GH pulse magnitude 3-5x greater than either compound alone, mimicking the natural physiological GH release pattern more closely than exogenous HGH. This blend is the preferred starting point for GH optimization in anti-aging, body recomposition, and recovery protocols.

Structure & Chemistry

  • Category: GH SECRETAGOGUE / ANTI-AGING / RECOVERY
  • Molecular size: CJC: ~3.37 kDa | Ipamorelin: ~0.81 kDa (pre-mixed in single vial)

Regulatory & Research Status

  • FDA: Neither component approved for human use. Both removed from Category 2 compounding ban (Sept 2024) for PCAC review, compounding still prohibited pending outcome.
  • WADA: Both compounds Prohibited S2, CJC as GHRH Analog, Ipamorelin as GH Secretagogue. Banned in and out of competition.
  • Evidence: Zero human RCTs on the combination specifically. The 3-5x synergy figure is from pharmacodynamic modeling and animal studies, not confirmed in human clinical trials.

Specifications

Presentation 5mg single vial
Purity >99% by HPLC
Form Lyophilized powder (reconstitute with bacteriostatic water for laboratory use)
Category GH SECRETAGOGUE / ANTI-AGING / RECOVERY
For laboratory and research use only. Not for human or animal consumption. Not approved by the FDA for any therapeutic use. No claims regarding therapeutic efficacy are made or implied. Must be 21 or older.

Related Research

Related products